| Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment AT Ruffin, H Li, L Vujanovic, DP Zandberg, RL Ferris, TC Bruno Nature Reviews Cancer 23 (3), 173-188, 2023 | 148 | 2023 |
| Impact of exercise on oocyte quality in the POLG mitochondrial DNA mutator mouse C Faraci, S Annis, J Jin, H Li, K Khrapko, DC Woods Reproduction 156 (2), 185-194, 2018 | 13 | 2018 |
| 856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and … DP Zandberg, DA Clump, BR Isett, R Bao, H Wang, L Vujanovic, H Li, ... Annals of Oncology 34, S557-S558, 2023 | 7 | 2023 |
| Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC). RL Ferris, WE Gooding, SI Chiosea, U Duvvuri, S Kim, M Kubik, ... Journal of Clinical Oncology 41 (16_suppl), 6018-6018, 2023 | 5 | 2023 |
| CD8 T CELL REPERTOIRE ANALYSIS OF PATIENTS WITH RESECTABLE HEAD AND NECK CANCER ENROLLED IN A PHASE II NEOADJUVANT STUDY OF a-PD1 ADMINISTERED ALONE OR IN COMBINATION WITH … P Santos, A Kulkarni, H Li, J Chen, L Vujanovic, S Kim, U Duvvuri, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 10, A713-A713, 2022 | 2 | 2022 |
| Single, long molecule PCR for the detection of rare mutations in Mitochondrial DNA H Li, S Annis, D Woods, J Tilly, K Khrapko The FASEB Journal 31, 634.7-634.7, 2017 | 1 | 2017 |
| Differential impact of TIM-3 ligands on NK cell function J Wang, H Li, A Kulkarni, JL Anderson, P Upadhyay, OV Onyekachi, ... Journal for Immunotherapy of Cancer 13 (1), e010618, 2025 | | 2025 |
| 520 Galectin-9 affects distinct natural killer cell functions through TIM-3 and CD44 J Wang, H Li, A Kulkarni, J Anderson, P Upadhyay, OV Onyekachi, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 493 Distinct correlative signatures of CD4+ helper and regulatory T cells associate with response to different neoadjuvant immune checkpoint inhibitor combinations in HNSCC M Brand, A Kulkarni, H Li, P Upadhyay, S Chiosea, PM Santos, B Isett, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC H Li, P Santos, A Kulkarni, B Isett, J Marion, S Chiosea, U Duvvuri, S Kim, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Discovery of Human Papilloma Virus and patient-specific neoantigens targeted by CD8+ T cells in HNSCC VKK Makani, H Li, A Kulkarni, S Arshad, L Vujanovic, RL Ferris, ... The Journal of Immunology 210 (1_Supplement), 89.18-89.18, 2023 | | 2023 |
| 1037 Single cell evaluation of antigen specificity, clonal dynamics and transcriptional signatures of CD8+ T cells in head and neck squamous carcinoma H Li, P Santos, A Kulkarni, A Joglekar, L Vujanovic, R Ferris Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 683 CD8 T cell repertoire analysis of patients with resectable head and neck cancer enrolled in a phase II neoadjuvant study of α-PD1 administered alone or in combination with … P Santos, A Kulkarni, H Li, J Chen, L Vujanovic, S Kim, U Duvvuri, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Friend or Foe: Can Mitochondrial Toxins Lead to Similar Benefits as Exercise? S Annis, A Safdar, E Biala, A Saleem, H Li, P Gandhi, Z Fleischmann, ... Mitochondrial Dysfunction Caused by Drugs and Environmental Toxicants, 475-485, 2018 | | 2018 |
